window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

NMPA

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Biogen’s felzartamab approved in China for multiple myeloma

    Biogen’s felzartamab has been approved in China as a treatment [...]

    August 27, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    China approves Symproic for opioid-induced constipation

    China’s National Medical Products Administration has approved Shionogi’s Symproic for [...]

    June 11, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Calibre secures CQC registration for nationwide AI health service
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Research & Development
  • Cyllene gene therapy for bladder disorder gains FDA RMAT designation
    Categories: Drug Discovery & Development
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top